

PROTOCOL CODE: MYDBLDFTI

Cycle 9 and onward

(Page 1 of 3)

Patient RevAid # _____

DOCTOR'S ORDERS Ht _____ cm Wt _____ kg BSA _____ m²

REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form

DATE: _____ **To be given:** _____ **Cycle #:** _____

Date of Previous Cycle: _____

Risk Category: **Female of Childbearing Potential (FCBP) Rx valid for 7 days**

Risk Category: **Male or Female of non-Childbearing Potential (NCBP)**

****Ensure Red Blood Cell Phenotype and Group and Screen for all patients prior to Cycle 1****

Delay treatment _____ week(s)

CBC & Diff day of treatment

Proceed with all medications for entire cycle as written, if within 96 hours of Day 1: **ANC greater than or equal to 1.0 x 10⁹/L, platelets greater than or equal to 50 x 10⁹/L, and eGFR or creatinine clearance as per protocol**

Dose modification for: **Hematology:** _____ **Other Toxicity:** _____

Proceed with treatment based on blood work from _____

LENALIDOMIDE
One cycle = 28 days
 • Ensure antiviral VZV prophylaxis is in place

lenalidomide* _____ mg PO daily, in the evening, on Days 1 to 21 and off for 7 days
 lenalidomide* _____ mg PO _____

(*available as 25 mg, 20mg, 15 mg, 10 mg, 5 mg and 2.5 mg capsules)
 *Note: Use one capsule strength for the total dose; there are cost implications as costing is per capsule and not weight based

FCBP dispense 21 capsules (1 cycle)
 For Male and Female NCBP:

Dispense: _____ capsules or _____ cycles. Maximum 63 capsules (3 cycles).
 Pharmacy to dispense one cycle at a time, maximum 3 cycles if needed

Physician to ensure DVT prophylaxis in place: ASA, warfarin, low molecular weight heparin, direct oral anticoagulant or none (select one)

Pharmacy Use for
Lenalidomide dispensing:
 Part Fill # 1
 RevAid confirmation number: _____
 Lenalidomide lot number: _____
 Pharmacist counsel (initial): _____

Part Fill # 2
 RevAid confirmation number: _____
 Lenalidomide lot number: _____
 Pharmacist counsel (initial): _____

Part Fill # 3
 RevAid confirmation number: _____
 Lenalidomide lot number: _____
 Pharmacist counsel (initial): _____

Special Instructions

DOCTOR'S SIGNATURE:

Physician Revaid ID: _____

SIGNATURE:

UC: _____

PROTOCOL CODE: MYDBLDFTI
Cycle 9 and onward

(Page 2 of 3)

DATE:

STEROID (select one)* RN to use patient's therapeutic steroid (if applicable) as pre-med for daratumumab

- dexamethasone** **40 mg** or **20 mg** PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning x _____ doses OR number of 28 day cycles _____ OR
- dexamethasone** _____ **mg** PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning x _____ doses OR number of 28 day cycles _____ OR
- predniSONE** _____ **mg** PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning x _____ doses OR number of 28 day cycles _____ OR
- No Steroid

*Refer to Protocol for suggested dosing options

****Have Hypersensitivity Reaction Tray and Protocol Available****

DARATUMUMAB PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____

- Ensure antiviral VZV prophylaxis is in place

If no reaction after 4 consecutive doses of daratumumab, may discontinue acetaminophen, loratadine/diphenhydrAMINE and montelukast

dexamethasone as ordered in steroid section

- montelukast 10 mg** PO prior to each daratumumab dose
acetaminophen 650 mg PO prior to each daratumumab dose

Select one of the following:

- loratadine 10 mg** PO prior to each daratumumab dose

OR

- diphenhydrAMINE 50 mg** PO or IV prior to each daratumumab dose

TREATMENT:

daratumumab subcut 1800 mg (fixed dose in 15 mL) **subcutaneously** into abdomen over 5 minutes* **on Day 1**

x _____ **cycle(s)** (max 3 cycles)

NB: During treatment with subcutaneous daratumumab, administer other subcutaneous drugs at alternative injection sites whenever possible

DOCTOR'S SIGNATURE:

SIGNATURE:

UC:

PROTOCOL CODE: MYDBLDFTI

Cycle 9 and onward

(Page 3 of 3)

DATE:

RETURN APPOINTMENT ORDERS

- Return in **four** weeks for Doctor and Cycle _____. Book treatment on Day 1.
- Return in **eight** weeks for Doctor and Cycles _____. Book treatment x 2 cycles (on Day 1).
- Return in **twelve** weeks for Doctor and Cycles _____. Book treatment x 3 cycles (on Day 1).

CBC & Diff, creatinine, total bilirubin, ALT, alkaline phosphatase, calcium, albumin, LDH, serum protein electrophoresis and serum free light chain levels every 4 weeks

TSH every 3 months (i.e. prior to Cycles 10, 13, 16 etc)

- urine protein electrophoresis** every 4 weeks
- immunoglobulin panel (IgA, IgG, IgM)** every 4 weeks
- urea, sodium, potassium** every 4 weeks
- CBC & Diff** Days 8, 15, 22
- creatinine, sodium, potassium** Days 8, 15, 22
- total bilirubin, ALT, alkaline phosphatase** Days 8, 15, 22
- calcium, albumin** Days 8, 15, 22
- Quantitative beta-hCG blood test for FCBP** 7-14 days and 24 h prior to Cycle 1 and every week for 4 weeks during Cycle 1
- Quantitative beta- hCG blood test for FCBP**, every 4 weeks, less than or equal to 7 days prior to the next cycle
- HBV viral load** prior to next cycle
- See general orders sheet for additional requests**
- Other tests:**
- Consults:**

DOCTOR'S SIGNATURE:

SIGNATURE:

UC: